专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010083611A1 METHOD FOR THE PREVENTION AND TREATMENT OF DIASTOLIC DYSFUNCTION EMPLOYING AN APOLIPOPROTEINA1 (APOA1) MIMETIC PEPTIDE/PHOSPHOLIPID COMPLEX 审中-公开
标题翻译：预防和治疗使用APOLIPOPROTEINA1（APOA1）的纤维蛋白肽/磷脂复合物的脱水性功能障碍的方法
公开(公告)号：WO2010083611A1
公开(公告)日：2010-07-29
申请号：PCT/CA2010/000108
申请日：2010-01-25
申请人： INSTITUT DE CARDIOLOGIE DE MONTREAL , TARDIF, Jean-Claude , BUSSEUIL, David , RHEAUME, Eric
发明人： TARDIF, Jean-Claude , BUSSEUIL, David , RHEAUME, Eric
IPC分类号： A61K38/17 , A61P9/00
CPC分类号： A61K38/1709 , A61K31/00
摘要： A method of treating a diastolic dysfunction in a mammal comprising administering a therapeutically effective amount of a reverse lipid transport agonist to said mammal. The most preferred agonist is an Apolipoprotein-A1 (APO-A1) mimetic peptide/phospholipid complex.
摘要翻译：一种治疗哺乳动物舒张功能障碍的方法，包括向所述哺乳动物施用治疗有效量的反向脂质转运激动剂。最优选的激动剂是载脂蛋白-A1（APO-A1）模拟肽/磷脂复合物。

2. 发明申请

WO2004091608A1 DECREASING THE INCIDENCE OF ATRIAL FIBRILLATION (AF) IN PATIENTS WITH LEFT VENTRICULAR DYSFUNCTION WITH ACE INHIBITORS OR ANGIOTENSIN II RECEPTOR ANTAGONISTS 审中-公开
标题翻译：降低患有ACE抑制剂或血管紧张素II受体拮抗剂的左室功能障碍患者的急性心律失常
公开(公告)号：WO2004091608A1
公开(公告)日：2004-10-28
申请号：PCT/CA2004/000568
申请日：2004-04-15
申请人： INSTITUT DE CARDIOLOGIE DE MONTRÉAL / MONTRÉAL HEART INSTITUTE , DUCHARME, Anique , TARDIF, Jean-Claude , BOURASSA, Martial G.
发明人： DUCHARME, Anique , TARDIF, Jean-Claude , BOURASSA, Martial G.
IPC分类号： A61K31/401
CPC分类号： A61K31/472 , A61K31/00 , A61K31/401 , A61K31/403 , A61K31/41 , A61K31/4178 , A61K31/4184
摘要： Atrial fibrillation (AF) is frequently encountered in patients with heart failure (HF) and is also a predictor of morbidity and mortality in this population. Recent experimental studies have shown electrical and structural atrial remodeling with increased fibrosis in HF animals, and have suggested a preventive effect of angiotensin converting enzyme inhibitors (ACEi) on the development of AF. To verify the hypothesis that ACEi prevent the development of AF in patients with HF, a retrospective analysis of the patients from the Montreal Heart Institute (MHI) included in the Studies Of Left Ventricular Dysfunction (SOLVD) was conducted. The results of this retroactive analysis indicate that treatment with the ACE inhibitor, such as enalapril, can markedly reduce the risk of developing atrial fibrillation in patients with left ventricular dysfunction.
摘要翻译：心力衰竭（HF）患者经常遇到心房颤动（AF），并且也是该人群发病率和死亡率的预测因子。最近的实验研究显示HF动物纤维化增加的电和结构性心房重塑，并提出血管紧张素转换酶抑制剂（ACEi）对AF发展的预防作用。为了验证ACEI预防HF患者房颤发生的假说，对包括在左心室功能障碍（SOLVD）研究中的蒙特利尔心脏病学研究所（MHI）的患者进行回顾性分析。这种追溯分析的结果表明，使用ACE抑制剂（如依那普利）治疗可以显着降低患有左心室功能障碍患者心房颤动的风险。

3. 发明申请

WO03028571A2 METHOD FOR IDENTIFICATION AND VISUALIZATION OF ATRIAL TISSUE AND THERAPEUTICAL USE THEREOF 审中-公开
标题翻译：方法用于鉴定和可视化的ATRIAL组织及其治疗方法
公开(公告)号：WO03028571A2
公开(公告)日：2003-04-10
申请号：PCT/CA0201449
申请日：2002-09-24
申请人： INST CARDIOLOGIE MONTREAL , DUBUC MARC , GUERRA PETER , TARDIF JEAN-CLAUDE
发明人： DUBUC MARC , GUERRA PETER , TARDIF JEAN-CLAUDE
IPC分类号： A61B8/12 , A61B19/00 , A61B18/14
CPC分类号： A61B90/36 , A61B8/12 , A61B2090/3784
摘要： The present invention relates to a method for visual identification of atrial tissue comprising the steps of visualizing a site of atrial tissue formation using a device adapted for visualizing and obtaining an image; and analyzing the image to determine the presence, location and/or distribution of atrial tissue in the site. The present invention also relates to a method for the treatment of atrial fibrillation in a patient, comprising the steps of identifying atrial tissue in a site of atrial tissue formation by introducing a device adapted for visualization into the site; and substantially ablating atrial tissue previously identified. The present invention further relates to a method for determining the shape of an atrial tissue formation comprising the step of identifying atrial tissue site potential indicative of the shape of the atrial tissue.
摘要翻译：本发明涉及一种用于视觉鉴定心房组织的方法，包括以下步骤：使用适于可视化和获得图像的装置可视化心房组织形成部位; 并分析图像以确定该部位中心房组织的存在，位置和/或分布。本发明还涉及一种用于治疗患者心房颤动的方法，包括以下步骤：通过将适于可视化的装置引入所述部位来鉴定心房组织形成部位的心房组织; 并且基本上消融先前鉴定的心房组织。本发明还涉及一种用于确定心房组织形状的方法，其包括鉴定表征心房组织形状的心房组织位置电位的步骤。

4. 发明申请

WO2009152619A1 A METHOD OF DETECTING A SUBJECT AT RISK OF, OR HAVING, AN INDICATION ASSOCIATED WITH CORONARY ARTERY DISEASE 审中-公开
标题翻译：检测与冠状动脉疾病相关的指征的风险或伴有的主体的方法
公开(公告)号：WO2009152619A1
公开(公告)日：2009-12-23
申请号：PCT/CA2009/000854
申请日：2009-06-17
申请人： INSTITUT DE CARDIOLOGIE DE MONTRÉAL , UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW , TARDIF, Jean-Claude , COLIN, Berry , RHEAUME, Eric
发明人： TARDIF, Jean-Claude , COLIN, Berry , RHEAUME, Eric
IPC分类号： G01N33/68 , G01N33/483 , G01N33/543 , G01N35/00
CPC分类号： G01N33/6893 , G01N33/5091 , G01N2333/52 , G01N2800/324
摘要： There are disclosed methods and biomarkers for detecting an indication associated with, or risk of, coronary artery disease In an embodiment, a method includes obtaining a sample including bone marrow-derived cells and a growth factor; measuring a ratio of cell count of the cells and concentration of growth factor, and determining, based on the ratio of the cells and the concentration of the growth factor, risk of coronary artery disease In another embodiment, a biomarker includes a ratio of a cell count of bone marrow-deπved cells and a concentration of a growth factor, measured in a biological sample including the bone marrow-derived cells and the growth factor, the ratio of the cell count of the bone marrow-derived cells and the concentration of the growth factor measured in the sample, determining whether the subject has the indication associated with coronary artery disease Other embodiments are also disclosed.
摘要翻译：公开了用于检测与冠状动脉疾病相关的指征或风险的方法和生物标志物。在一个实施方案中，一种方法包括获得包含骨髓来源的细胞和生长因子的样品; 测量细胞的细胞计数和生长因子的浓度，并且基于细胞的比例和生长因子的浓度来确定冠状动脉疾病的风险。在另一个实施方案中，生物标志物包括细胞比例在包括骨髓来源的细胞和生长因子的生物样品中测量的骨髓去除细胞计数和生长因子浓度，骨髓来源的细胞的细胞计数和在样品中测量的生长因子，确定受试者是否具有与冠状动脉疾病相关的指征。还公开了其他实施方案。

5. 发明申请

WO2007137400A1 METHOD AND COMPOUND FOR THE TREATMENT OF VALVULAR STENOSIS 审中-公开
标题翻译：治疗瓣膜狭窄的方法和化合物
公开(公告)号：WO2007137400A1
公开(公告)日：2007-12-06
申请号：PCT/CA2007/000895
申请日：2007-05-23
申请人： INSTITUT DE CARDIOLOGIE DE MONTREAL , TARDIF, Jean-Claude
发明人： TARDIF, Jean-Claude
IPC分类号： A61K38/17 , A61K31/661 , A61K31/688 , A61P9/10
CPC分类号： A61K31/00 , A61K31/683 , A61K31/688 , A61K38/1709 , A61K2300/00
摘要： A method for treating valvular stenosis The method involves the administration of a therapeutically effective amount of a reverse lipid ( in particular cholesterol) transport agonist to a mammal Most preferred is an Apolipoprotein A-1 mimetic peptide/phospholipid complex, the peptide of which is defined by the amino acid sequence of SEQ ID NO 1.
摘要翻译：用于治疗瓣膜狭窄的方法该方法包括将治疗有效量的反向脂质（特别是胆固醇）转运激动剂给予哺乳动物最优选的是载体载体载体蛋白A-1模拟肽/磷脂复合物，其肽被定义由SEQ ID NO 1的氨基酸序列。

6. 发明申请

WO2004080482A2 METHOD AND COMPOUND TO REDUCE THE INCIDENCE OF DIABETES IN A SUBJECT WITH CHRONIC HEART FAILURE 审中-公开
标题翻译：降低糖尿病患者慢性心脏衰竭的方法和化合物
公开(公告)号：WO2004080482A2
公开(公告)日：2004-09-23
申请号：PCT/CA2004/000243
申请日：2004-02-17
申请人： INSTITUT DE CARDIOLOGIE DE MONTRÉAL / , BOURASSA, Martial, G. , TARDIF, Jean-Claude , DUCHARME, Anique
发明人： BOURASSA, Martial, G. , TARDIF, Jean-Claude , DUCHARME, Anique
IPC分类号： A61K38/55
CPC分类号： A61K31/40 , A61K31/41 , A61K38/556 , A61K45/06
摘要： The present invention relates to the effect of angiotensin-converting enzyme (ACE) inhibitors on the prevention of diabetes in a subject with left ventricular dysfunction. A retrospective study was conducted to assess the effect of the ACE inhibitor enalapril on the incidence of diabetes in a group of patients from the Montreal Heart Institute enrolled in the Studies of Left Ventricular Dysfunction (SOLVD). Clinical charts were evaluated for fasting plasma glucose (FPG) levels by blinded reviewers. A diagnosis of diabetes was made when a FPG 126 mg/dL (7 mmol/L) was found at 2 visits (follow-up, 2.9±1.0 years). Of the 291 non-diabetic patients enrolled in the SOLVD study, 153 of these were on enalapril and 138 were on placebo. Baseline characteristics were similar in the 2 groups. Forty patients developed diabetes during follow-up, 9 (5.9%) in the enalapril group and 31(22.4%) in the placebo group (P
摘要翻译：本发明涉及血管紧张素转化酶（ACE）抑制剂对预防左心室功能障碍患者糖尿病的作用。进行了一项回顾性研究，以评估ACE抑制剂依那普利对参加“左心室功能障碍研究”（SOLVD）研究的蒙特利尔心脏病研究组患者糖尿病发病率的影响。盲法评估者对空腹血糖（FPG）水平评估临床表现。当2次访视（随访，2.9±1.0年）发现FPG为126 mg / dL（7 mmol / L）时，进行糖尿病诊断。在参加SOLVD研究的291例非糖尿病患者中，其中153例为依那普利，138例为安慰剂。两组基线特征相似。随访期间，40例患者发生糖尿病，依那普利组为9例（5.9％），安慰剂组为31例（22.4％）（P <0.0001）。通过多变量分析，依那普利仍然是发展中糖尿病风险降低最有力的预测指标（风险比为0.22; 95％置信区间，0.10至0.46; P <0.0001）。因此，依那普利可显着降低左心室功能障碍患者的糖尿病发病率，特别是FPG受损患者。

7. 发明申请

WO2008099091A2 UTILISATION DE L'IVABRADINE POUR L'OBTENTION DE MEDICAMENTS DESTINES AU TRAITEMENT DE LA DYSFONCTION ENDOTHELIALE 审中-公开
标题翻译：用于生产用于治疗内皮功能障碍的药物的依巴沙丁的用途
公开(公告)号：WO2008099091A2
公开(公告)日：2008-08-21
申请号：PCT/FR2008/000027
申请日：2008-01-10
申请人： LES LABORATOIRES SERVIER , BENATAR, Vidal , LEREBOURS-PIGEONNIERE, Guy , TARDIF, Jean-claude , THORIN, Eric , RHEAUME, Eric
发明人： BENATAR, Vidal , LEREBOURS-PIGEONNIERE, Guy , TARDIF, Jean-claude , THORIN, Eric , RHEAUME, Eric
IPC分类号： A61K31/55
CPC分类号： A61K31/55
摘要： Utilisation de l'ivabradine ou 3-{3-[{[(7S)-3,4-diméthoxybicyclo[4.2.0]octa-1,3,5-trién-7-yl]-methyl}-(methyl)-amino]-propyl}-7,8-diméthoxy-1,3,4,5-tétrahydro-2 H -3-benzazépin-2-one, de ses sels d'addition à un acide pharmaceutiquement acceptable et de leurs hydrates, pour l'obtention d'un médicament destiné au traitement de Ia dysfonction endothéliale.
摘要翻译：伊伐布雷定或3- {3 - [{[（7S）-3,4-二甲氧基双环[4.2.0]辛-1,3,5-三嗪 -7-基] - 甲基} - （甲基） - 氨基] - 丙基} -7,8-暗淡é甲氧基-1,3,4,5- T E四氢-2的 H ^ 的-3- 苯并二氢吡喃-2-酮，其加成盐; 药学上可接受的酸及其水合物，用于获得用于医药产品的药物; 来治疗内皮功能障碍。

8. 发明申请

WO2007041868A1 METHOD FOR DETECTING A BIOMARKER OF OXIDATIVE STRESS IN A BIOLOGICAL SAMPLE 审中-公开
标题翻译：用于检测生物样品中氧化应激生物标志物的方法
公开(公告)号：WO2007041868A1
公开(公告)日：2007-04-19
申请号：PCT/CA2006/001696
申请日：2006-10-13
申请人： INSTITUT DE CARDIOLOGIE DE MONTREAL , DES ROSIERS, Christine , ASSELIN, Caroline , BOUCHARD, Bertrand , TARDIF, Jean-Claude , COMTE, Blandine
发明人： DES ROSIERS, Christine , ASSELIN, Caroline , BOUCHARD, Bertrand , TARDIF, Jean-Claude , COMTE, Blandine
IPC分类号： G01N33/53 , A61K31/00 , A61K31/10 , A61P9/00 , G01N33/483 , G01N33/50
CPC分类号： G01N33/5091 , G01N2800/32
摘要： The present invention relates to methods for detecting a oxidative stress in a biological sample, methods of determining a cumulative record of oxidative injury, and methods of diagnosing diseases of aging, such as cardiovascular diseases, based on the presence or absence of a biomarker or a component thereof. The present invention also relates to a kit for detecting oxidative stress in a biological sample comprising a stabilizing reactant and an antibody.
摘要翻译：本发明涉及用于检测生物样品中的氧化应激的方法，确定氧化损伤的累积记录的方法，以及基于生物标志物的存在或不存在的，诸如心血管疾病的老化疾病的诊断方法其组分。本发明还涉及用于检测包含稳定反应物和抗体的生物样品中的氧化应激的试剂盒。

9. 发明申请

WO2004080482A3 USE OF ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS TO PREVENT DIABETES IN A SUBJECT WITH CHRONIC HEARTH FAILURE 审中-公开
标题翻译：使用血管紧张素转换酶（ACE）抑制剂以预防患有慢性心脏衰竭的受试者的糖尿病
公开(公告)号：WO2004080482A3
公开(公告)日：2004-11-11
申请号：PCT/CA2004000243
申请日：2004-02-17
申请人： INST CARDIOLOGIE MONTREAL , BOURASSA MARTIAL G , TARDIF JEAN-CLAUDE , DUCHARME ANIQUE
发明人： BOURASSA MARTIAL G , TARDIF JEAN-CLAUDE , DUCHARME ANIQUE
IPC分类号： A61K31/40 , A61K31/41 , A61K38/55 , A61K45/06 , A61P3/10 , A61P9/00
CPC分类号： A61K31/40 , A61K31/41 , A61K38/556 , A61K45/06
摘要： The present invention relates to the effect of angiotensin-converting enzyme (ACE) inhibitors on the prevention of diabetes in a subject with left ventricular dysfunction. A retrospective study was conducted to assess the effect of the ACE inhibitor enalapril on the incidence of diabetes in a group of patients from the Montreal Heart Institute enrolled in the Studies of Left Ventricular Dysfunction (SOLVD). Clinical charts were evaluated for fasting plasma glucose (FPG) levels by blinded reviewers. A diagnosis of diabetes was made when a FPG 126 mg/dL (7 mmol/L) was found at 2 visits (follow-up, 2.9±1.0 years). Of the 291 non-diabetic patients enrolled in the SOLVD study, 153 of these were on enalapril and 138 were on placebo. Baseline characteristics were similar in the 2 groups. Forty patients developed diabetes during follow-up, 9 (5.9%) in the enalapril group and 31(22.4%) in the placebo group (P
摘要翻译：本发明涉及血管紧张素转化酶（ACE）抑制剂对预防左心室功能障碍患者糖尿病的作用。进行了一项回顾性研究，以评估ACE抑制剂依那普利对参加“左心室功能障碍研究”（SOLVD）研究的蒙特利尔心脏病研究组患者糖尿病发病率的影响。盲法评估者对空腹血糖（FPG）水平评估临床表现。当2次访视（随访，2.9±1.0年）发现FPG为126 mg / dL（7 mmol / L）时，进行糖尿病诊断。在参加SOLVD研究的291例非糖尿病患者中，其中153例为依那普利，138例为安慰剂。两组基线特征相似。随访期间，40例患者发生糖尿病，依那普利组为9例（5.9％），安慰剂组为31例（22.4％）（P <0.0001）。通过多变量分析，依那普利仍然是发展中糖尿病风险降低最有力的预测指标（风险比为0.22; 95％置信区间，0.10至0.46; P <0.0001）。因此，依那普利可显着降低左心室功能障碍患者的糖尿病发病率，特别是FPG受损患者。

10. 发明申请

WO2003028571A3 METHOD FOR IDENTIFICATION AND VISUALIZATION OF ATRIAL TISSUE 审中-公开
公开(公告)号：WO2003028571A3
公开(公告)日：2003-04-10
申请号：PCT/CA2002/001449
申请日：2002-09-24
申请人： INSTITUT DE CARDIOLOGIE DE MONTREAL , DUBUC, Marc , GUERRA, Peter , TARDIF, Jean-Claude
发明人： DUBUC, Marc , GUERRA, Peter , TARDIF, Jean-Claude
IPC分类号： A61B19/00
摘要： The present application relates to a method for visual identification of atrial tissue comprising the steps of visualizing a site of atrial tissue formation using a device adapted for visualizing and obtaining an image; and analyzing the image to determine the presence, location and/or distribution of atrial tissue in the site. The present application also discloses to a method for the treatment of atrial fibrillation in a patient, comprising the steps of identifying atrial tissue in a site of atrial tissue formation by introducing a device adapted for visualization into the site; and substantially ablating atrial tissue previously identified. The present application invention further discloses a method for determining the shape of an atrial tissue formation comprising the step of identifying atrial tissue site potential indicative of the shape of the atrial tissue.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式